Article
LKB1/KRAS mutant lung cancers constitute a genetic subset of NSCLC with increased sensitivity to MAPK and mTOR signalling inhibition.
British journal of cancer - 27 Jan 2009
Mahoney C L, Choudhury B, Davies H, Edkins S, Greenman C, Haaften G van, Mironenko T, Santarius T, Stevens C, Stratton M R, Futreal P A
Abstract excerpt
LKB1/STK11 is a multitasking tumour suppressor kinase. Germline inactivating mutations of the gene are responsible for the Peutz-Jeghers hereditary cancer syndrome. It is also somatically inactivated in approximately 30% of non-small-cell lung cancer (NSCLC). Here, we report that LKB1/KRAS mutant NSCLC cell lines are sensitive to the MEK inhibitor CI-1040 shown by a dose-dependent reduction in proliferation rate,...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.